Vídeos del Professor Hendrik Tobias Arkenau

Career in Medical...Dr Hendrik-Tobias Arkenau, Medical Director at SCRI U подробнее

Dr Hendrik-Tobias Arkenau is the medical director of Sarah Cannon Research Institute UK, a stand-alone clinical trial facility dedicated to developing new anti-cancer drugs and therapies. On a daily basis, Dr Arkenau works closely with his team to ensure a high standard of care and treatment is provided to patients, and clinical trial data is delivered timely and accurately to research partners in the pharmaceutical industry. Watch full video on http://www.10minuteswith.com/interview/dr-hendrik-tobias-arkenau-medical-director-scri-uk

Dr Hendrik-Tobias Arkenau подробнее

Dr. Arkenau has vast experience in early oncology clinical drug development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. Before joining Sarah Cannon Research UK, he was senior clinical fellow at the Royal Marsden Hospital and team leader for early drug development at the Prince of Wales Clinical School at the University of New South Wales, Sydney, Australia.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer подробнее

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon as potential treatments for patients with gastric cancer.

Dr. Arkenau Discusses the Future of Immunotherapy in Melanoma подробнее

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma. In the past, the initial successful data of CTLA-4 blockade with ipilimumab resulted in a response rate of about 10%. Today, there are combinations with ipilumumab and evolumab, with response rates in the range of 60%, so there have been very strong results. Arkenau says it is exciting that the response rates are improving with these combinations and result in prolonged progression-free survival.

Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer подробнее

Dr Hendrik Tobias Arkenau подробнее

Dr. Arkenau on Survival Data With TAS-102 in Gastric Cancer подробнее

Immunotherapy clinical trials for cancer patients подробнее

Dr Hendrik Tobias Arkenau, a leading medical oncologist from the renowned Sarah Cannon Research Institute in London, explains what cancer clinical trials involve, and more specifically what immunotherapy clinical trials are like. He also explains how cancer patients should go about requesting information about active clinical trials, should they be suitable for inclusion. Book an appointment with Dr Arkenau here: https://www.topdoctors.co.uk/doctor/h...

How does immunotherapy work? подробнее

Immunotherapy is a type of cancer treatment that aims to manipulate the way our own immune system recognises and fights cancer cells. Dr Hendrik Tobias Arkenau, a prominent medical oncologist from the Sarah Cannon Research Insitute in London, explains in more detail what cancer immunotherapy is and how it differs to other cancer treatments, such as chemotherapy. Book a consultation with Dr Arkenau: https://www.topdoctors.co.uk/doctor/h...

What are the side effects of immunotherapy? подробнее

Immunotherapy for cancer treatment can sometimes produce certain side effects. However, these side effects are very different to those of other cancer treatments, such as chemotherapy, and are generally more of an inflammatory nature, which could affect any part of the body. Dr Hendrik Tobias Arkenau, a leading medical oncologist at the Sarah Cannon Research Institute in London, explains in more detail the possible side effects of immunotherapy and what patients should do if they experience them. Book a consultation with Dr Arkenau: https://www.topdoctors.co.uk/doctor/h...

How successful is immunotherapy? подробнее

Immunotherapy cancer treatment in the last 10 years has shown great success in a variety of different types of cancer. Dr Hendrik Tobias Arkenau, a leading medical oncologist at the Sarah Cannon Research Institute in London, explains the success we've seen so far with immunotherapies, and also what the future of immunotherapy cancer treatment holds. Book an appointment now with Dr Arkenau: https://www.topdoctors.co.uk/doctor/h...